Title:
IMMUNOTOXIN COMPRISING RIBONUCLEASE FUSED TO CYTOTRANSMAB
Document Type and Number:
WIPO Patent Application WO/2019/132579
Kind Code:
A2
Abstract:
The present invention relates to the development of a recombinant immunotoxin in which a cytotransmab, which penetrates into the cytosol of a target cell, is fused to a ribonuclease (RNase). Particularly, the present invention relates to a novel recombinant cytotransmab-RNase (CT-RNase, CT-R) immunotoxin in which a cytotransmab (CT) which can be internalized into target cells through a membrane protein and then released into the cytosol due to endosomal escape ability is fused to a human-derived RNase lacking cytosol penetrating ability whereby the RNase can be delivered to the cytosol of target cells, a construction method therefor, and a use thereof. Exhibiting the characteristics of penetrating into the cytosol of a target tumor cell and exerting RNase activity-caused cytotoxicity to inhibit tumor growth and induce cell death, the cytotransmab-RNase immunotoxin according to the present invention can find applications in a pharmaceutical composition for tumor treatment and prevention.
Inventors:
KIM YONG SUNG (KR)
KIM JI SUN (KR)
PARK JAE YEONG (KR)
KIM JI SUN (KR)
PARK JAE YEONG (KR)
Application Number:
PCT/KR2018/016844
Publication Date:
July 04, 2019
Filing Date:
December 28, 2018
Export Citation:
Assignee:
ORUM THERAPEUTICS INC (KR)
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF:
Previous Patent: BOX HOLDER
Next Patent: POLYAMIDE RESIN COMPOSITION AND MOLDED ARTICLE COMPRISING SAME
Next Patent: POLYAMIDE RESIN COMPOSITION AND MOLDED ARTICLE COMPRISING SAME